ADHD : UPDATE ON DIAGNOSIS AND TREATMENT

2020 Michael J. Bresnan Continuing Medical Education Course in Child Neurology

DAVID K. URION, M.D., FAAN

DIRECTOR, BEHAVIORAL NEUROLOGY CLINICS AND PROGRAMS DIRECTOR OF EDUCATION CHARLES F. BARLOW CHAIR DEPT. OF NEUROLOGY BOSTON CHILDREN'S HOSPITAL

DISCLOSURES

- I HAVE NO DISCLOSURES OF FINANCIAL SIGNIFICANCE
- I HAVE RECEIVED NO COMPENSATION FOR THIS TALK
- I AM THE AUTHOR OF CHAPTER ON ADHD, NELSON'S TEXTBOOK OF PEDIATRICS, 20th and 21st editions

GOALS AND OBJECTIVES

- Identify the changes in the DSM-5 definition of ADHD which have changed clinical assessment
- Discuss how to choose evaluation tools for older children presenting with ADHD
- Explain newer formulations of dopaminergic stimulants and their rational use

DIFFERENTIAL DIAGNOSIS

EPIDEMIOLOGY

BEST STUDIES SHOW THAT 5 - 7% NORTH AMERICAN POPULATION MEET DSM-5 CRITERIA

• THIS IS A PRIMARY CARE PROBLEM

EPIDEMIOLOGY, CONT.

RESEARCH SHOWS ISLANDS OF HIGH DIAGNOSIS, IN A SEA OF UNDERDIAGNOSIS

 RESEARCH SHOWS CERTAIN GROUPS MORE LIKELY TO BE DIAGNOSED, OTHERS LESS SO

CURRENT DSM-5 FORMULATION

- DIVIDES INTO ATTENTION DISORDERS WITH AND WITHOUT HYPERACTIVITY, AND MIXED TYPE
- UTILIZES CRITERIA BASED UPON CHILD HAVING MORE OF A CHARACTERISTIC BEHAVIOR THAN IS USUAL FOR AGE
- UNCHANGED FROM DSM-IV-TR

CURRENT, CONT.

- ISSUES MUST BE PRESENT IN TWO OR MORE
 SETTINGS AND IDENTIFIED BY TWO
 INDEPENDENT OBSERVERS
- MUST APPEAR BEFORE AGE 12 YEARS
- MUST NOT BE BETTER EXPLAINED BY SOME OTHER
 NEUROLOGIC OR PSYCHIATRIC DIAGNOSIS
- MUST BE CAUSING PROBLEMS

THUS

- The categorical descriptions of the disorder and its subtypes are fundamentally unchanged from DSM-IV
- The two most significant changes are a widening of the age of onset and the requirement for different informants from two different settings

AGE OF ONSET

 The evidence basis for this was good, in that examination of accuracy of parental recall showed that the previous standard was unrealistic

AGE OF ONSET, CONT.

- The practical implications, however, are significant
- We now must be clear that certain disorders that have attentional symptoms as prominent early signs, and manifest between ages 7 and 12, are not present

EXPANDED DIFFERENTIAL DIAGNOSIS FOR ADHD

- Leukodystrophies
 - X-linked adrenoleukodystrophy
 - Metachromatic leukodystrophy
 - Vanishing White Matter Disease

THIS DOES NOT MEAN

- Every child between ages 7 and 12 years needs an imaging study
- It does mean we need to do a neurologic examination for these children which can address these issues


SOME BASIC RULES

- Affected WM is HYPERINTENSE on T2
- Less pronounced in hypomyelinating syndromes
- Some hypomyelinating disorders are associated with peripheral neuropathies
- Otherwise, describe lesions as
 - Confluent
 - Isolated
 - Multifocal

CONFLUENT LESIONS

Distribution is very helpful

Normal Myelination




Schiffmann, R. et al. Neurology 2009;72:750-759



Copyright © 2020 Boston Children's Hospital



Abnormal myelin A: Alexander B: X-ALD C: Kearnes-Sayre D: MLD E: NCL F: central hypomyelination/vanishing white matter G: cerebrotendinous xanthomatosis H: adult-onset AD leukodystrophy (LMNB1)



Schiffmann, R. et al. Neurology 2009;72:750-759



Copyright © 2020 Boston Children's Hospital



EXPANDED DDX FOR ADHD, CONT.

- Psychiatric Disorders
 - Juvenile bipolar disorder
 - Anxiety Disorders
 - Oppositional Defiant Disorder
 - Intermittent Explosive Disorder

EXPANDED DDX FOR ADHD

- Medications
 - Antiepileptic drugs
 - INH
 - Sympathomimetics
 - Neuroleptics
 - Thyroid hormone replacement

EXPANDED DDX FOR ADHD

- Substance abuse
- Physical and sexual abuse

TWO INFORMANTS

- Comes from work which showed that parental assessment of teacher attribution and teacher's own attribution were significantly discordant
- Thus, cannot make diagnosis without data from parents and teachers

CHOICE OF AGENT

CHOICE OF AGENT

Should be based upon the patient's needs, based upon some basic knowledge of their day, when they need effect from medication, and medication profiles

CHOICE OF AGENT

Thus, we need to know basic pharmacokinetics of the agents

AGENTS		
Press Contraction		
AGENTTYPE	FUNCTIONALT 1/2	
DEXTROAMPHETAMINE	X	
METHYLPHENIDATE	1.5X	
DEXTROAMPHETAMINE SP	1.5 – 1.75 X	
RACEMIC AMPHETAMINE	2X	
MEPHEN SR	2.25X	
RACEMIC AMPH SR	2.5 – 2.75X	
OROS MEPHEN	2.625 – 3 X	
BEAD DISPERSAL MEPHEN	2.75 – 3.25×	
TRANSDERMAL MEPHEN	3 – 3.5×	
LISDEXAMFETAMINE	3 – 3.5X	

AMPHETAMINES


AGENTTYPE	FUNCTIONALT 1/2
DEXTROAMPHETAMINE	X
DEXTROAMPHETAMINE SP	1.5 – 1.75X
RACEMIC AMPHETAMINE	2X
RACEMIC AMPH SR	2.25X
LISDXAMFETAMINE	3 – 3.5X


METHYLPHENIDATE

AGENTTYPE	FUNCTIONALT 1/2
METHYLPHENIDATE	Y
SR MEPH	I.5 Y
OROS MEPH	1.75 – 2Y
BEAD DISPERSAL MEPH	I.8-2.2Y
TRANSDERMAL MEPH	2 – 2.3Y

DOSING RANGES


- For methylphenidate, most people respond in doses between 0.5 – 1.5 mg/kg/day
- For amphetamine compounds, most people respond in doses between 0.25 – 0.75 mg/kg/day






ASSESSMENT OF THE OLDER CHILD

- Vanderbilt Rating Scale is validated through 12 years of age
- It may underreport comorbid symptoms, so in those settings a second scale may be helpful








AN EXAMPLE

- You are caring for a 10 year old boy with a well-established diagnosis of ADHD
- He weighs 30 kg, and is on 20 mg of methylphenidate CD taken each morning
- His family reports that his attention is said to flag by 1400 at school, and he struggles with homework



THIS IS MY MOTIVE MOST SUBLIME TO MAKE THE PUNISHMENT FIT THE CRIME

THE MIKADO

AS VOLTAIRE TAUGHT US

"A physician is someone who prescribes medications, about which they know little, for diseases, about which they know less, to human beings, about whom they know nothing at all."